Daxor (DXR) vs LeMaitre Vascular (LMAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LeMaitre Vascular (LMAT) has outperformed Daxor (DXR) over the past year, losing 9.5% versus a loss of 21.9%. Over five years, LMAT leads with a +48.6% price change compared with -6.6% for DXR. LeMaitre Vascular is the larger company by market cap ($1.82 billion vs $61.1 million), about 29.8 times the size.
On valuation, Daxor trades at a lower trailing P/E (9.6x vs 27.9x for LeMaitre Vascular). LeMaitre Vascular pays a dividend yielding 1.13%, while Daxor does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXR | LMAT |
|---|---|---|
| Share price | $10.46 | $79.64 |
| Market cap | $61.07M | $1.82B |
| 1-day change | +1.01% | +0.42% |
| YTD return | -28.75% | -1.80% |
| 1-year return | -21.86% | -9.54% |
| 5-year return | -6.58% | +48.64% |
| P/E ratio (TTM) | 9.60 | 27.94 |
| Forward P/E | — | 25.05 |
| EPS (TTM) | $1.09 | $2.85 |
| Dividend yield | 0.00% | 1.13% |
| Annual dividend | $0.00 | $0.90 |
| 52-week high | $14.76 | $118.01 |
| 52-week low | $8.56 | $78.22 |
| Distance from 52-week high | -29.13% | -32.51% |
| Analyst consensus | none | buy |
| Avg. price target upside | +91.20% | +34.35% |
| Average volume | 17.23K | 330.14K |
| Shares outstanding | 5.84M | 22.87M |
| Employees | — | 646 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Medical Instruments & Supplies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LeMaitre Vascular is about 29.8 times larger than Daxor by market value ($1.82B vs $61.07M).
- LMAT has outperformed DXR by 12.3 percentage points over the past year.
- LeMaitre Vascular trades at a higher earnings multiple (27.9x vs 9.6x trailing P/E).
- LeMaitre Vascular offers a meaningfully higher dividend yield (1.13% vs 0.00%).
About Daxor
DXR stock →Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.
Healthcare · Medical Instruments & Supplies
About LeMaitre Vascular
LMAT stock →LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
Healthcare · Medical Instruments & Supplies · 646 employees
DXR vs LMAT FAQ
Which is bigger, Daxor or LeMaitre Vascular?
LeMaitre Vascular (LMAT) is larger, with a market capitalization of $1.82B compared with $61.07M for Daxor (DXR).
Which stock has performed better over the past year, DXR or LMAT?
LMAT returned -9.54% over the past 12 months, compared with -21.86% for DXR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DXR or LMAT?
DXR has the lower trailing P/E at 9.6, versus 27.9 for LMAT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Daxor or LeMaitre Vascular?
LeMaitre Vascular pays a dividend yielding 1.13%, while Daxor does not currently pay a regular dividend.
Are Daxor and LeMaitre Vascular in the same industry?
Yes. Both are classified in the Medical Instruments & Supplies industry within the Healthcare sector.